Fibrinolysin therapy in thromboembolic disease. 1961

W A RANDOLPH, and H M STARLING

UI MeSH Term Description Entries
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D013923 Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolisms

Related Publications

W A RANDOLPH, and H M STARLING
December 1962, New York state journal of medicine,
W A RANDOLPH, and H M STARLING
September 1959, Produits pharmaceutiques,
W A RANDOLPH, and H M STARLING
August 1959, Angiology,
W A RANDOLPH, and H M STARLING
January 1962, Bulletin de la Societe internationale de chirurgie,
W A RANDOLPH, and H M STARLING
January 1958, Archivos. Hospital Universitario General Calixto Garcia,
W A RANDOLPH, and H M STARLING
August 1959, Angiology,
W A RANDOLPH, and H M STARLING
January 1961, JAMA,
W A RANDOLPH, and H M STARLING
May 1962, Pathologie et biologie,
W A RANDOLPH, and H M STARLING
April 1951, Rhode Island medical journal,
W A RANDOLPH, and H M STARLING
January 1961, The Heart bulletin,
Copied contents to your clipboard!